サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1684413

組み込みタンパク質治療薬CDMOの世界市場：種類別・適応症・供給源別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Recombinant Protein Therapeutics CDMO Market, By Type, By Indication, By Source, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 316 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
組み込みタンパク質治療薬CDMOの世界市場：種類別・適応症・供給源別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

組み込みタンパク質治療薬CDMOの市場規模は2024年に209億2,032万米ドルとなり、2025年から2032年までのCAGRは13.98%に拡大

組み込みタンパク質治療薬CDMOの市場力学

生物製剤の需要増加とバイオプロセス技術の市場開拓が市場需要を促進する見込み

組み込みタンパク質治療薬CDMO市場の成長は、生物製剤の需要増加とその製造の複雑さが相まって、製薬会社やバイオテクノロジー企業が専門のCDMOに依存するようになったことが背景にあります。オリジナルの生物製剤の費用対効果の高いバージョンであるバイオシミラーは市場で受け入れられつつあり、組み込みタンパク質治療薬CDMOサービスの需要をさらに押し上げ、市場の成長を後押ししています。シングルユース・バイオリアクター、連続製造、高収率発現システム（CHO細胞やHEK293細胞など）により、タンパク質生産の効率が向上しています。上流および下流工程における技術革新は、タンパク質の収率を向上させ、生産コスト全体と生産期間を短縮しています。

個別化医療と精密治療の台頭により、カスタマイズされた組換えタンパク質への需要が高まっています。組換えタンパク質をベースとした細胞療法や遺伝子療法は、先端生物製剤におけるCDMOの役割を拡大しています。さらに、腫瘍学、希少疾患、再生医療における新たな用途が市場の成長を促進しています。アジア太平洋、特に中国、インド、韓国は、低コストと政府の支援政策により、バイオ医薬品製造の拠点となりつつあります。そのため、多くのCDMOがこれらの地域に施設を設置し、手頃な価格の生物製剤に対する需要の高まりに対応しています。

組み込みタンパク質治療薬CDMO市場：主な考察

リサーチアナリストの分析によると、世界市場は予測期間（2025-2032年）に約13.98%のCAGRで毎年成長すると推定されます。

種類別では、インターフェロンセグメントは、感染症の高い有病率により、2024年に最大の市場シェアを示すと予測されました。

適応症別では、有病率の高い疾患によるタンパク質治療薬の需要の高さから、2024年にはその他セグメントが主要適応症セグメントとなりました。

供給源別では、ヒト糖タンパク質への応用が高いことから、哺乳類システムセグメントが2024年のソースセグメントをリードしています。

地域別では、北米が2024年の主要収益源でした。これは、政府の支援政策と輸送分野の開発によるものです。

組み込みタンパク質治療薬CDMO市場：セグメンテーション分析

組み込みタンパク質治療薬CDMOの世界市場は、種類、適応症、供給源、地域に基づいて区分されます。

市場は種類別に、成長ホルモン、インターフェロン、ワクチン、免疫賦活剤、その他に分類されます。市場を独占しているのはインターフェロンです。主に感染性疾患の有病率の増加が、同分野の成長に拍車をかけています。

市場は適応症別に、がん、感染症、免疫疾患、代謝疾患、血液疾患、その他の6つに分類されます。その他分野は最大のシェアを占めると予想されます。予測期間中、最も速い速度で成長すると予想されるのは代謝性疾患分野です。

同市場は供給源に基づき、哺乳類システム、微生物システム、その他の3つのカテゴリーに分類されます。ソース別では哺乳類システムが最大シェアを占めています。生物学的薬剤、遺伝子工学への応用が増加しており、市場成長を後押しすると予測されています。

組み込みタンパク質治療薬CDMO市場：地域別分析

組み込みタンパク質治療薬CDMO市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広がっています。組み込みタンパク質治療薬CDMO市場では、北米が突出した地位を占めています。米国は組換えタンパク質医薬品の生産において世界的リーダーとしての地位を確立しています。同国の強力な研究開発インフラと整備されたバイオ医薬品製造能力が市場成長に寄与しています。アジア太平洋地域は、組み込みタンパク質治療薬CDMO市場で大きな成長を遂げようとしています。その要因としては、慢性疾患の有病率の上昇、ヘルスケア支出の増加、バイオテクノロジーへの投資の拡大などが挙げられ、成長機会をもたらしています。中東とアフリカは、組み込みタンパク質治療薬CDMO市場の成長が緩やかです。

組み込みタンパク質治療薬CDMO市場：競合情勢

市場参入企業は、組み換えタンパク質を含むバイオ医薬品の開発・製造に関する包括的なサービスを提供しています。中には、治療用タンパク質の開発・製造に特化し、細胞株開発から商業生産までのサービスを提供している企業もあります。

目次

第1章 組み込みタンパク質治療薬CDMO市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 組み込みタンパク質治療薬CDMOの主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 組み込みタンパク質治療薬CDMO市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 組み込みタンパク質治療薬CDMO市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 組み込みタンパク質治療薬CDMOの市場情勢

  • 組み込みタンパク質治療薬CDMOの市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 組み込みタンパク質治療薬CDMO市場：種類別

  • 概要
    • セグメント別シェア分析：種類別
    • 成長ホルモン
    • インターフェロン
    • ワクチン
    • 免疫刺激剤
    • その他

第8章 組み込みタンパク質治療薬CDMO市場：適応症別

  • 概要
    • セグメント別シェア分析：適応症別
    • 腫瘍学
    • 感染症
    • 免疫疾患
    • 代謝障害
    • 血液疾患
    • その他

第9章 組み込みタンパク質治療薬CDMO市場：供給源別

  • 概要
    • セグメント別シェア分析：供給源別
    • 哺乳類システム
    • 微生物システム
    • その他

第10章 組み込みタンパク質治療薬CDMO市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：組み込みタンパク質治療薬CDMO業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Richter-Helm BioLogics
    • Lonza
    • Catalent, Inc
    • FUJIFILM Diosynth Biotechnologies
    • WuXi Biologics
    • Curia Global, Inc.
    • Batavia Biosciences BV
    • AGC Biologics
    • Boehringer Ingelheim BioXcellence
    • Repligen Corporation
    • Therapure BioPharma Inc.
    • Cytovance Biologics
    • KBI Biopharma
    • Abzena
    • Patheon
    • Others

第12章 AnalystViewの全方位的分析

目次
Product Code: ANV4798

REPORT HIGHLIGHT

Recombinant protein therapeutics CDMO Market size was valued at USD 20,920.32 Million in 2024, expanding to a CAGR of 13.98% from 2025 to 2032.

Recombinant protein therapeutics CDMO is specialized in recombinant protein therapeutics that provides services to biotech and pharmaceutical companies for the development, production, and scaling of protein-based drugs. These companies help in the end-to-end process, including cell line development, upstream and downstream processing, analytical testing, regulatory compliance, and large-scale manufacturing.

Recombinant protein therapeutics CDMO Market- Market Dynamics

Increasing demand for biologics and development in bioprocessing technologies are expected to propel market demand

The recombinant protein therapeutics CDMO market growth is driven by increasing demand for biologics, combined with the complexity of their production, has driven pharmaceutical and biotech companies to rely on specialized CDMOs. Biosimilars, which are cost-effective versions of original biologics, are gaining market acceptance, further driving the demand for CDMO services in recombinant protein production, boosting market growth. Single-use bioreactors, continuous manufacturing, and high-yield expression systems (such as CHO and HEK293 cells) have enhanced the efficiency of protein production. Innovations in upstream and downstream processing have improved protein yields, reducing overall production costs and timelines.

The rise of personalized medicine and precision therapeutics has increased demand for customized recombinant proteins. Recombinant protein-based cell and gene therapies are expanding the role of CDMOs in advanced biologics. Further, emerging applications in oncology, rare diseases, and regenerative medicine are fueling market growth. Asia-Pacific, particularly China, India, and South Korea, is becoming a hub for biopharmaceutical manufacturing due to lower costs and supportive government policies. Thus, many CDMOs are setting up facilities in these regions to cater to the growing demand for affordable biologics.

Recombinant protein therapeutics CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 13.98% over the forecast period (2025-2032)

Based on Type segmentation, the interferons segment was predicted to show maximum market share in the year 2024, due to high prevalence of infectious diseases.

Based on Indication segmentation, the others segment was the leading Indication segment in 2024, due to the high demand for protein therapeutics due to high prevalence disorders.

Based on Source segmentation, the mammalian systems segment was the leading Source segment in 2024, due to their high applications in human glycoproteins.

On the basis of region, Norh America was the leading revenue generator in 2024, owing to supportive government policies & development in transportation sector.

Recombinant protein therapeutics CDMO Market- Segmentation Analysis:

The Global Recombinant protein therapeutics CDMO Market is segmented on the basis of Type, Indication, Source, and Region.

The market is divided into five categories based on Type: growth hormones, interferons, vaccines, immunostimulant agents, and others. The interferons segment dominates the market. The increasing prevalence of infectious disorders is mainly spurring segment growth.

The market is divided into six categories based on Indication: oncology, infectious diseases, immunological disorders, metabolic disorders, hematological disorders, and others. The others segment is expected to hold the largest share. The metabolic disorders segment is expected to grow at the fastest rate over the forecast period.

The market is divided into three categories based on Source: mammalian system, microbial systems, and others. The mammalian systems segment holds the largest share of the source segment. The increasing applications biological drugs, genetical engineering are anticipated to bolster market growth.

Recombinant protein therapeutics CDMO Market- Geographical Insights

Across the world, the Recombinant protein therapeutics CDMO market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a prominent position in the recombinant protein therapeutics CDMO market. The United States has established itself as a global leader in the production of recombinant protein drugs. The country's strong research and development infrastructure and well-developed biopharmaceutical manufacturing capabilities contribute to market growth. The Asia-Pacific region is poised for significant growth in the recombinant protein therapeutics CDMO market. Factors contributing to this include a rising prevalence of chronic diseases, increased healthcare expenditures, and growing investments in biotechnology are offering growth opportunities. The Middle East and Africa are experiencing moderate growth in the recombinant protein therapeutics CDMO market.

Recombinant protein therapeutics CDMO Market- Competitive Landscape:

The recombinant protein therapeutics CDMO market is characterized by intense competition, with several key players striving to enhance their service offerings and expand their market presence. market participants offer a comprehensive range of services for the development and manufacture of biopharmaceuticals, including recombinant proteins. Some of the companies specialize in the development and manufacturing of therapeutic proteins, providing services from cell line development to commercial production.

Recent Developments:

In 2024, Novo Holdings announced a USD 16.5 billion acquisition of Catalent, planning to expand production capabilities for its successful weight-loss drugs.

In June 2023, Richter-Helm BioLogics announced the plan for the development of a production site in Bovenau, Europe.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET KEY PLAYERS

  • Richter-Helm BioLogics
  • Lonza
  • Catalent, Inc
  • FUJIFILM Diosynth Biotechnologies
  • WuXi Biologics
  • Curia Global, Inc.
  • Batavia Biosciences B.V.
  • AGC Biologics
  • Boehringer Ingelheim BioXcellence
  • Repligen Corporation
  • Therapure BioPharma Inc.
  • Cytovance Biologics
  • KBI Biopharma
  • Abzena
  • Patheon
  • Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

  • Growth hormones
  • Interferons
  • Vaccines
  • Immunostimulant agents
  • Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

  • Oncology
  • Infectious Diseases
  • Immunological disorders
  • Metabolic disorders
  • Hematological disorders
  • Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY SOURCE- MARKET ANALYSIS, 2019-2032

  • Mammalian system
  • Microbial systems
  • Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Recombinant Protein Therapeutics CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Recombinant Protein Therapeutics CDMO Market Snippet by Type
    • 2.1.2. Recombinant Protein Therapeutics CDMO Market Snippet by Indication
    • 2.1.3. Recombinant Protein Therapeutics CDMO Market Snippet by Source
    • 2.1.4. Recombinant Protein Therapeutics CDMO Market Snippet by Country
    • 2.1.5. Recombinant Protein Therapeutics CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Recombinant Protein Therapeutics CDMO Key Market Trends

  • 3.1. Recombinant Protein Therapeutics CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Recombinant Protein Therapeutics CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Recombinant Protein Therapeutics CDMO Market Opportunities
  • 3.4. Recombinant Protein Therapeutics CDMO Market Future Trends

4. Recombinant Protein Therapeutics CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Recombinant Protein Therapeutics CDMO Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Recombinant Protein Therapeutics CDMO Market Landscape

  • 6.1. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Recombinant Protein Therapeutics CDMO Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Growth hormones
    • 7.1.3. Interferons
    • 7.1.4. Vaccines
    • 7.1.5. Immunostimulant agents
    • 7.1.6. Others

8. Recombinant Protein Therapeutics CDMO Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Infectious Diseases
    • 8.1.4. Immunological disorders
    • 8.1.5. Metabolic disorders
    • 8.1.6. Hematological disorders
    • 8.1.7. Others

9. Recombinant Protein Therapeutics CDMO Market - By Source

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Source, 2024 & 2032 (%)
    • 9.1.2. Mammalian system
    • 9.1.3. Microbial systems
    • 9.1.4. Others

10. Recombinant Protein Therapeutics CDMO Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Recombinant Protein Therapeutics CDMO Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Richter-Helm BioLogics
    • 11.2.2. Lonza
    • 11.2.3. Catalent, Inc
    • 11.2.4. FUJIFILM Diosynth Biotechnologies
    • 11.2.5. WuXi Biologics
    • 11.2.6. Curia Global, Inc.
    • 11.2.7. Batavia Biosciences B.V.
    • 11.2.8. AGC Biologics
    • 11.2.9. Boehringer Ingelheim BioXcellence
    • 11.2.10. Repligen Corporation
    • 11.2.11. Therapure BioPharma Inc.
    • 11.2.12. Cytovance Biologics
    • 11.2.13. KBI Biopharma
    • 11.2.14. Abzena
    • 11.2.15. Patheon
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us